Table 3.
ORs and 95% CIs of prostate cancer, by plasma level of lipid-adjusted organochlorine.
| Quartile category |
|||||
|---|---|---|---|---|---|
| Plasma level | Low | Second | Third | High | p for trend |
| o,p′-DDT (ng/g lipid) | < 2.5 | 2.5–4.2 | 4.3–7.6 | ≥ 7.7 | |
| Cases/controls (n) | 43/99 | 57/99 | 54/101 | 47/103 | |
| OR (95% CI) | 1.00 | 1.36 (0.81–2.27) | 1.27 (0.73–2.20) | 1.07 (0.59–1.94) | 0.69 |
| ORa (95% CI) | 1.00 | 1.39 (0.79–2.44) | 1.29 (0.71–2.34) | 1.04 (0.54–2.03) | 0.61 |
| p,p′-DDT (ng/g lipid) | < 24 | 24–40 | 41–63 | ≥ 64 | |
| Cases/controls (n) | 41/94 | 64/105 | 50/101 | 46/102 | |
| OR (95% CI) | 1.00 | 1.43 (0.86–2.38) | 1.14 (0.67–1.96) | 1.02 (0.57–1.83) | 0.59 |
| ORa (95% CI) | 1.00 | 1.51 (0.87–2.63) | 0.92 (0.50–1.70) | 1.00 (0.52–1.92) | 0.45 |
| p,p′-DDE (ng/g lipid) | < 560 | 560–939 | 940–1599 | ≥ 1,600 | |
| Cases/controls (n) | 49/98 | 52/100 | 47/94 | 53/110 | |
| OR (95% CI) | 1.00 | 1.04 (0.64–1.69) | 1.00 (0.61–1.64) | 0.96 (0.58–1.59) | 0.79 |
| ORa (95% CI) | 1.00 | 1.00 (0.60–1.66) | 0.89 (0.52–1.53) | 0.90 (0.52–1.54) | 0.65 |
| trans-Nonachlor (ng/g lipid) | < 50 | 50–74 | 75–119 | ≥ 120 | |
| Cases/controls (n) | 49/96 | 56/102 | 44/96 | 52/108 | |
| OR (95% CI) | 1.00 | 1.07 (0.66–1.75) | 0.83 (0.47–1.46) | 0.83 (0.43–1.62) | 0.54 |
| ORa (95% CI) | 1.00 | 1.11 (0.67–1.86) | 0.92 (0.49–1.69) | 0.86 (0.42–1.78) | 0.61 |
| cis-Nonachlor (ng/g lipid) | < 9.1 | 9.1–12.9 | 13–20.9 | ≥ 21 | |
| Cases/controls (n) | 52/100 | 48/85 | 50/111 | 51/106 | |
| OR (95% CI) | 1.00 | 1.07 (0.66–1.73) | 0.83 (0.50–1.38) | 0.84 (0.45–1.54) | 0.54 |
| ORa (95% CI) | 1.00 | 1.13 (0.67–1.89) | 0.83 (0.48–1.43) | 0.80 (0.41–1.57) | 0.46 |
| Oxychlordane (ng/g lipid) | < 17 | 17–23.9 | 24–36.9 | ≥ 37 | |
| Cases/controls (n) | 46/89 | 64/107 | 42/102 | 49/104 | |
| OR (95% CI) | 1.00 | 1.14 (0.69–1.88) | 0.75 (0.43–1.30) | 0.77 (0.39–1.53) | 0.32 |
| ORa (95% CI) | 1.00 | 1.06 (0.61–1.82) | 0.74 (0.40–1.36) | 0.75 (0.34–1.64) | 0.40 |
| HCB (ng/g lipid) | < 34 | 34–54.9 | 55–84.9 | ≥ 85 | |
| Cases/controls | 54/98 | 48/102 | 57/97 | 42/105 | |
| OR (95% CI) | 1.00 | 0.71 (0.37–1.36) | 0.78 (0.38–1.62) | 0.49 (0.21–1.12) | 0.09 |
| ORa (95% CI) | 1.00 | 0.78 (0.38–1.57) | 0.86 (0.40–1.88) | 0.52 (0.21–1.25) | 0.11 |
| Mirex (ng/g lipid) | < 3.1 | 3.1–4.0 | 4.1–5.9 | ≥ 6.0 | |
| Cases/controls (n) | 57/97 | 38/104 | 50/98 | 56/103 | |
| OR (95% CI) | 1.00 | 0.59 (0.34–0.996) | 0.84 (0.51–1.39) | 0.95 (0.54–1.67) | 0.66 |
| ORa (95% CI) | 1.00 | 0.54 (0.30–0.97) | 0.85 (0.49–1.46) | 1.14 (0.61–2.13) | 0.22 |
| β-HCH (ng/g lipid) | < 200 | 200–319 | 320–519 | ≥ 520 | |
| Cases/controls (n) | 52/99 | 50/97 | 56/105 | 43/101 | |
| OR (95% CI) | 1.00 | 0.98 (0.61–1.59) | 1.00 (0.62–1.62) | 0.78 (0.46–1.33) | 0.33 |
| ORa (95% CI) | 1.00 | 0.89 (0.52–1.50) | 0.85 (0.50–1.46) | 0.56 (0.30–1.01) | 0.05 |
| Total PCBs (ng/g lipid) | < 319 | 319–447 | 448–668 | ≥ 669 | |
| Cases/controls (n) | 67/131 | 49/89 | 41/91 | 44/91 | |
| OR (95% CI) | 1.00 | 1.08 (0.66–1.77) | 0.86 (0.51–1.44) | 0.89 (0.49–1.61) | 0.64 |
| ORa (95% CI) | 1.00 | 1.06 (0.63–1.79) | 0.84 (0.49–1.46) | 0.97 (0.51–1.87) | 0.90 |
a
Adjusted for smoking status, alcohol intake, marital status, body mass index, and intake of green tea and miso soup.
Adjusted ORs were calculated based on subjects with complete information on covariates.